Abstract
Liver damage in diabetes mellitus is of particular interest, since this factor significantly affects the course of the disease, the level of compensation and prognosis of the underlying disease.
 The aim. To study the effect of complex treatment using ursosan on the functional state of the hepatobiliary system in patients with diabetes mellitus.
 Materials and methods. The study included 30 patients with type 1 diabetes mellitus and 48 patients with type 2 diabetes. According to the duration of diabetes, patients were divided into three subgroups: a) up to five years; b) 5–10 years; c) more than 10 years. The number of patients was: 1a group – 13, 1b group – 10, 1c group – 7 people; Group 2a – 23, 2b group – 13, 2c group – 10 people. The control group consisted of 23 apparently healthy people. Ursosan was prescribed at a dose of 10-12 mg per 1 kg of body per day for 6 months. Clinical laboratory and instrumental research methods were used to study the functional state of the liver and gallbladder.
 Research results. After the course of treatment with Ursosan, patients with diabetes mellitus showed normalization of protein, pigment, enzymatic metabolism and, to a lesser extent, lipid metabolism in the liver, which led to an improvement in cellular metabolism and redox processes, providing a stable course of diabetes.
 Conclusions. A 6-month course of treatment with Ursosan in diabetic patients promotes long-term diabetes compensation. Patients during treatment have a decrease in cytolysis syndrome indicators (alanine aminotransferase (AlAT), aspartate aminotransferase (AsAT), lactate dehydrogenesis (LDH)) by about 1.5 times in all 3 indicators compared to the indicators before treatment. The same trend was observed in terms of gamma-glutamine transferase (GGT) and alkaline phosphatase (ALP)
Highlights
Diabetes mellitus (DM) has become a global health problem that threatens to reach pandemic levels by 2030 [1, 2]
DM is one of the diseases in which the liver is damaged more and more seriously; the treatment of this organ is of particular interest, since its damage significantly affects the course of the disease, the level of compensation and the prognosis of the disease [3,4,5]
It is known that ursodeoxycholic acid – UDCA, which is a hydrophilic non-toxic acid formed under the influence of bacterial enzymes from 7keto-lithocholic acid entering the liver from the small intestine – is of great importance in the treatment of liver diseases from various groups of drugs
Summary
Diabetes mellitus (DM) has become a global health problem that threatens to reach pandemic levels by 2030 [1, 2]. DM is one of the diseases in which the liver is damaged more and more seriously; the treatment of this organ is of particular interest, since its damage significantly affects the course of the disease, the level of compensation and the prognosis of the disease [3,4,5]. It is known that ursodeoxycholic acid – UDCA (drug Ursosan), which is a hydrophilic non-toxic acid formed under the influence of bacterial enzymes from 7keto-lithocholic acid entering the liver from the small intestine – is of great importance in the treatment of liver diseases from various groups of drugs. UDCA has antioxidant effects and attenuates cholestasis-induced immunosuppression. Prescribing UDCA is warranted in patients with cholestasis-related liver disease [7, 8]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
